## MÃ<sup>3</sup>nica Patricia Ballesteros Silva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/116989/publications.pdf

Version: 2024-02-01

31 626 14 24
papers citations h-index g-index

34 34 34 1249
all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	A Reporting Tool for Adapted Guidelines in Health Care: The RIGHT-Ad@pt Checklist. Annals of Internal Medicine, 2022, 175, 710-719.	3.9	16
2	Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. Journal of Medical Screening, 2021, 28, 389-404.	2.3	44
3	Teaching and learning how to make informed health choices: ÂProtocol for a context analysis in Spanish primary schools. F1000Research, 2021, 10, 312.	1.6	O
4	Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. Cancers, $2021, 13, 3001$ .	3.7	2
5	Teaching and learning how to make informed health choices: ÂProtocol for a context analysis in Spanish primary schools. F1000Research, 2021, 10, 312.	1.6	1
6	Barriers to Advance Care Planning Implementation in Health care: An Umbrella Review with Implications for Evidenceâ€Based Practice. Worldviews on Evidence-Based Nursing, 2021, 18, 254-263.	2.9	14
7	Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) $\hat{A}_{\ell}$ Is the Threshold of 20% Bone Marrow Blasts Reproducible?. Blood, 2021, 138, 2607-2607.	1.4	2
8	Current practices and challenges in adaptation of clinical guidelines: a qualitative study based on semistructured interviews. BMJ Open, 2021, 11, e053587.	1.9	8
9	Healthcare professionals' opinions, barriers and facilitators towards low-value clinical practices in the hospital setting. Gaceta Sanitaria, 2020, 34, 459-467.	1.5	5
10	COVIDâ€19 coagulopathy: An inâ€depth analysis of the coagulation system. European Journal of Haematology, 2020, 105, 741-750.	2.2	93
11	The UpPriority tool was developed to guide the prioritization of clinical guideline questions for updating. Journal of Clinical Epidemiology, 2020, 126, 80-92.	5.0	15
12	Evidence mapping and quality assessment of systematic reviews on therapeutic interventions for oral cancer. Cancer Management and Research, 2019, Volume 11, 117-130.	1.9	24
13	Delayed Hypersensitivity Reaction to Lenalidomide: 2 Different Clinical Patterns in the Same Patient. Journal of Investigational Allergology and Clinical Immunology, 2019, 29, 309-311.	1.3	1
14	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. Cancers, 2019, 11, 1364.	3.7	23
15	Colorectal cancer guidelines seldom include the patient perspective. Journal of Clinical Epidemiology, 2019, 116, 84-97.	<b>5.</b> 0	6
16	Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas. Clinical and Translational Oncology, 2019, 21, 1398-1412.	2.4	3
17	Extending the RIGHT statement for reporting adapted practice guidelines in healthcare: the RIGHT-Ad@pt Checklist protocol. BMJ Open, 2019, 9, e031767.	1.9	17
18	Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation. Seminars in Hematology, 2018, 55, 189-196.	3.4	6

#	Article	IF	CITATIONS
19	Methodological systematic review identifies major limitations in prioritization processes for updating. Journal of Clinical Epidemiology, 2017, 86, 11-24.	5.0	25
20	Development of a prioritisation tool for the updating of clinical guideline questions: the UpPriority Tool protocol. BMJ Open, 2017, 7, e017226.	1.9	11
21	Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST). BMC Medical Research Methodology, 2017, 17, 135.	3.1	18
22	Cancer randomized trials showed that dissemination bias is still a problem to be solved. Journal of Clinical Epidemiology, 2016, 77, 84-90.	5.0	4
23	The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC Hematology, 2016. 16. 14.	2.6	7
24	Interobserver variance in myelodysplastic syndromes with less than 5Â% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2Â% blasts. Annals of Hematology, 2015, 94, 565-573.	1.8	62
25	Description of the Protocols for Randomized Controlled Trials on Cancer Drugs Conducted in Spain (1999–2003). PLoS ONE, 2013, 8, e79684.	2.5	5
26	Inter-Observer Discordance With The Diagnosis Of Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts: Unilineage Vs Multilineage Dysplasia and Reproducibility Of The Threshold Of 2% Blasts. Blood, 2013, 122, 2768-2768.	1.4	0
27	False-positive Aspergillus Antigenemia Due to Blood Product Conditioning Fluids. Clinical Infectious Diseases, 2012, 55, e22-e27.	5.8	52
28	Validation of the FACT-G scale for evaluating quality of life in cancer patients in Colombia. Quality of Life Research, 2011, 20, 19-29.	3.1	41
29	Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells. Leukemia Research, 2009, 33, 395-406.	0.8	26
30	An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. Blood, 2009, 114, 5081-5090.	1.4	45
31	Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica De Mexico, 2008, 50, 276-285.	0.4	39